WebDisclosure WebDisclosure
Basculer en Français
10368 Companies
215967 Keywords
145710 Articles
114375 Press releases
Headlines Articles Press releases Aspire Biopharma, Inc. Remove
  1. Home
  2. Companies
  3. Aspire Biopharma, Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 02/19/2025 at 19:15, 1 year 2 months ago

    Aspire Biopharma Begins Trading on Nasdaq Following Merger

    Nasdaq Listing Business Combination Public Offering Drug Delivery Technology Aspire Biopharma
  • BRIEF

    published on 02/19/2025 at 19:15, 1 year 2 months ago

    Aspire Biopharma commence à être cotée au Nasdaq après sa fusion

    Technologie D'administration De Médicaments Cotation Au Nasdaq Regroupement D’entreprises Offre Publique De Vente Aspire Biopharma
  • PRESS RELEASE

    published on 02/19/2025 at 19:10, 1 year 2 months ago

    Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

    Aspire Biopharma and PowerUp Acquisition Corp. completed their business combination, enhancing access to capital and new product development. Shares to trade on Nasdaq as ASBP and ASBPW
    Nasdaq Business Combination Aspire Biopharma PowerUp Acquisition Corp. Drug Delivery Mechanism
    Logo of Aspire Biopharma, Inc.
Previous page
1 ... 6 7
Accesswire
  • Published on 05/08/2026 at 01:50, 41 minutes ago

    Apex Critical Metals Announces Grant of Stock Options and RSUs

  • Published on 05/08/2026 at 00:45, 1 hour 46 minutes ago

    Route1 Announces First Quarter 2026 Financial Results Notification

  • Published on 05/08/2026 at 00:00, 2 hours 31 minutes ago

    Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications

  • Published on 05/07/2026 at 23:30, 3 hours 1 minute ago

    Faraday Copper Reports First Quarter 2026 Financial Results

  • Published on 05/07/2026 at 23:15, 3 hours 16 minutes ago

    BULGOLD Adopts Semi-Annual Financial Reporting

View all ACCESSWIRE
EQS Group
  • Published on 05/07/2026 at 23:23, 3 hours 8 minutes ago

    H1 25/26: Challenging environment and significant changes in IT market // Revised forecast // Programme to boost competitiveness

  • Published on 05/07/2026 at 23:14, 3 hours 17 minutes ago

    EQS-Adhoc: All for One Group SE revises forecast for 2025/26 financial year // »Precision« programme to boost competitiveness approved

  • Published on 05/07/2026 at 22:05, 4 hours 26 minutes ago

    Univar Solutions Announces Leadership Evolution

  • Published on 05/07/2026 at 20:42, 5 hours 49 minutes ago

    RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

  • Published on 05/07/2026 at 18:46, 7 hours 45 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS
Les Echos
  • Published on 05/07/2026 at 19:15, 7 hours 16 minutes ago

    2026 Annual General Meeting: approval of all resolutions submitted to the Meeting

  • Published on 05/07/2026 at 19:15, 7 hours 16 minutes ago

    Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote

  • Published on 05/07/2026 at 19:06, 7 hours 25 minutes ago

    Disclosure of Share Capital and Voting Rights as of April 30, 2026

  • Published on 05/07/2026 at 19:06, 7 hours 25 minutes ago

    Déclaration du nombre d’actions et droits de vote au 30 avril 2026

  • Published on 05/07/2026 at 19:00, 7 hours 31 minutes ago

    ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy